UK's NHS Rejects Late-Stage Prostate Cancer Drug

The United Kingdom's National Health Service (NHS) recently announced that they will not cover the late-stage prostate cancer drug, cabazitaxel, which is marketed under the brand name Jevtana.

The National Institute for Health and Clinical Excellence (NICE) released a statement saying that they had evaluated the drug and determined that the high cost of the drug could not be justified by the relatively short increase in life expectancy. The group also said that they were concerned by some potential side effects of the drug.